Prelude Therapeutics (PRLD) Income towards Parent Company (2019 - 2026)

Prelude Therapeutics has disclosed Income towards Parent Company across 8 years of filings, most recently posting -$14.2 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$14.2 million, up 59.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$84.1 million (up 39.89% YoY), and the FY2025 annual result was -$104.6 million, up 25.16% from the prior year.
• Income towards Parent Company came in at -$14.2 million for Q1 2026 at Prelude Therapeutics, up from -$17.3 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$14.2 million in Q1 2026 to a low of -$37.4 million in Q4 2023.
• The 5-year median for Income towards Parent Company is -$32.4 million (2023), against an average of -$30.3 million.
• Across the five-year window, Income towards Parent Company plunged 37.88% in 2022 and jumped 59.03% in 2026, its largest moves.
• Prelude Therapeutics' Income towards Parent Company stood at -$33.4 million in 2022, then slipped by 11.96% to -$37.4 million in 2023, then increased by 9.49% to -$33.8 million in 2024, then soared by 48.72% to -$17.3 million in 2025, then grew by 18.28% to -$14.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$14.2 million (Q1 2026), -$17.3 million (Q4 2025), and -$20.4 million (Q3 2025), per Business Quant data.